TJ-M2010-5
- CAS No.
- 1357471-57-8
- Chemical Name:
- TJ-M2010-5
- Synonyms
- TJ-M2010-5;3-(4-Benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl)propanamide;1-Piperazinepropanamide, 4-(phenylmethyl)-N-(4-phenyl-2-thiazolyl)-;ischemia,MIRI,Anoxia,factor,MyD88,injury,reoxygenation,inhibit,reperfusion,differentiation,Inhibitor,remodeling,myocardial,MyD88,TLR,TJ-M-2010-5,myeloid,TJM20105,TJ M2010 5
- CBNumber:
- CB29739857
- Molecular Formula:
- C23H26N4OS
- Molecular Weight:
- 406.54
- MDL Number:
- MFCD34578278
- MOL File:
- 1357471-57-8.mol
TJ-M2010-5 Chemical Properties,Uses,Production
Biological Activity
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway[1][2]. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI)[2]. TJ-M2010-5 (40 μM) inhibits MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppresses MyD88 signaling in LPS (100 ng/mL)-responsive RAW 264.7 cells in vitro[1].TJ-M2010-5 (5-30 μM) prevents B cell proliferation and induces B cells apoptosis after stimulation with R848 (500 ng/mL)[3]. TJ-M2010-5 treatment statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue in a 10-week CAC mouse model[1].TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction, as well as TGF-β1 serum levels at seven weeks postinduction[1].
References
[1]. Lin Xie, et al. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer. J Natl Cancer Inst. 2015 Dec 28;108(4):djv364. [2]. Yan Miao,et al. Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury.Am J Transl Res. 2020 Sep 15;12(9):5151-5169.
TJ-M2010-5 Preparation Products And Raw materials
Raw materials
Preparation Products
TJ-M2010-5 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 | support@targetmol.com | United States | 19973 | 58 |
| Shanghai Chaolan Chemical Technology Center | QQ:65489617 15618227136 | info@SuperLan-chem.com | China | 9929 | 58 |
| MQ (shanghai) Pharmaceuticals Co., Ltd. | 13761635123 | 1014988033@qq.com | China | 4966 | 55 |
| Shanghai Dongyang Biotechnology Co., Ltd. | 0512-0512-13601744364 13601744364 | chemsharker@126.com | China | 896 | 58 |
| Guangzhou Younan Technology Co., Ltd | 020-020-82000279 18988968278 | sales@ubiochem.com | China | 4324 | 58 |
| Chunchuang (Wuhan) Technology Co., Ltd | 15342225168 | yutianchun2007@126.com | China | 10005 | 58 |
| Jinan Jiuli Biotechnology Co. , Ltd. | 15865264761 | 486064515@qq.com | China | 2599 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 15221909166 | product02@bidepharm.com | China | 63720 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 23963 | 58 |
| Nantong QuanYi Biotechnology Co., Ltd | 0513-66337626 18051384581 | sales@chemhifuture.com | China | 4551 | 58 |